Sabaa to unveil 2 COVID-19 drugs before year-end
Updated 10/27/2020 7:01:00 PM
ArabFinance: Sabaa International for Pharmaceutical and Chemical Industry (SIPC) expected to produce two medicines to treat coronavirus before the end of this year, head of the company's development department Rami al Hendawi told Al-Mal news website.
The company intends to launch 3 immunomodulatory drugs, al-Hendawi said.
The medicines production will be started before 2020’s end subject to regulatory approvals with the self-financed budget of EGP 15 million.
The production capacity of the medicines will be determined by the orders the company will receive from the hospitals and will be delivered through 3 weeks.
The company obtained earlier preliminary approval from the Egyptian Drug Authority to register Favipiravir (200 mg) tablet, one of the drugs used in the treatment of coronavirus.
Sabaa is an Egypt-based company engaged in the pharmaceutical sector. The company’s generic product portfolio includes products focused on different therapeutic categories.
